|Day Low/High||1.24 / 1.30|
|52 Wk Low/High||0.56 / 2.76|
Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time
Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world
Biocept and Ally Bridge to evaluate strategic opportunities in China for the Company's liquid biopsy platform
Prestigious Southern California health plan contracts with Biocept to make the Company's Target Selector™ tests available in-network for its patients with cancer
Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines®
Company's intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology
Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsy
Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancer
New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream
NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of Oregon
Company presentation set for March 22 at 1:00 p.m. ET
Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids
Stocks with insider trader activity include BA, WLL and BIOC
These under-$10 stocks are making big moves higher. Here's how to trade them from here.
Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.
Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.